DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Accelerating sustainability in Indian pharma industry
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Subscribe To Our Newsletter & Stay Updated
